We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Biogen Narrow Indications for Aduhelm to Reflect Clinical Trial Population
FDA, Biogen Narrow Indications for Aduhelm to Reflect Clinical Trial Population
Biogen and FDA have narrowed the treatment indications for Aduhelm (aducanumab), now recommending the antiamyloid antibody only for patients with mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).